- CEO:Layton Mills
CannPal (ASX:CP1) Stock Price
Disclaimer: Past performance is not an indicator of future performance.
CannPal (ASX:CP1) Company Overview
CannPal Animal Therapeutics Limited (ASX: CP1) is a listed animal health Company developing innovative and naturally derived plant-based therapeutic products for pets targeting the Endocannabinoid System that owners can trust are both safe and scientifically validated.
The Company has a research focus on cannabinoids, the active pharmaceutical ingredients extracted from the cannabis plant, to provide veterinarians and pet owners with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and animal health markets by developing innovative therapeutics that can influence the Endocannabinoid System with full regulatory approval for veterinary distribution.